Jefferies Group LLC Lowers GlaxoSmithKline plc (GSK) Price Target to GBX 1450

Marco Green
November 19, 2017

FMR LLC now owns 25,024,276 shares of the pharmaceutical company's stock worth $1,079,047,000 after buying an additional 1,389,238 shares during the period. The company presently has an average rating of "Hold" and an average price target of GBX 1,569.75 ($20.65).

Several other equities research analysts have also recently issued reports on the company.

Dodge & Cox increased its investment in Glaxosmithkline Plc by 14,828,450 shares in its quarterly SEC filing. The Fcm Investments holds 10,350 shares with $446,000 value, down from 29,567 last quarter. The value of the position overall is up by 0.6%. Jefferies Group LLC reissued a "buy" rating and set a GBX 1,900 ($24.99) price target on shares of GlaxoSmithKline plc in a report on Thursday, July 13th. King Luther Capital Management Corp now owns 5,432 shares of the pharmaceutical company's stock valued at $234,000 after buying an additional 55 shares during the last quarter. The total value of its holdings increased 0.6%. About shares traded. ALJ Regional Holdings, Inc. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 3,374 shares of the pharmaceutical company's stock valued at $137,000 after buying an additional 64 shares during the last quarter. The Company's principal business activities are conducted through its subsidiary, Pacific Continental Bank, an OR state-chartered bank with deposits insured by the Federal Deposit Insurance Corporation. With 24,600 avg volume, 2 days are for Alj Regional Holdings Incorporated (NASDAQ:ALJJ)'s short sellers to cover ALJJ's short positions. GlaxoSmithKline plc has a one year low of GBX 1,311 ($17.24) and a one year high of GBX 1,724.50 ($22.68). The firm has a market capitalization of $85,410.00, a price-to-earnings ratio of 12.40, a price-to-earnings-growth ratio of 1.94 and a beta of 1.00. The firm had revenue of GBX 784.30 billion for the quarter. Shareholders of record on Thursday, November 9th will be given a dividend of GBX 19 ($0.25) per share. This represents a $1.93 annualized dividend and a dividend yield of 4.66%. This is a positive change from GlaxoSmithKline PLC's previous quarterly dividend of $0.49. The ex-dividend date of this dividend is Thursday, November 9th. GlaxoSmithKline PLC's dividend payout ratio (DPR) is 159.20%. Atria Investments Llc sold 7,105 shares as Glaxosmithkline Plc (GSK)'s stock rose 5.47%. TheStreet upgraded shares of GlaxoSmithKline PLC from a "c+" rating to a "b" rating in a report on Wednesday, October 25th.

GlaxoSmithKline plc (LON:GSK) last issued its earnings results on Wednesday, October 25th. The stock of GlaxoSmithKline plc (LON:GSK) has "Neutral" rating given on Monday, January 18 by J.P. Morgan.

September 21 investment analysts at J P Morgan Chase & Co reiterated a "Neutral" rating on the stock. GlaxoSmithKline PLC presently has an average rating of "Hold" and an average target price of $44.33. Also, insider Simon Dingemans acquired 1,076 shares of GlaxoSmithKline plc stock in a transaction that occurred on Thursday, October 12th. The purchase was disclosed in a document filed with the SEC, which is available through this link.

ILLEGAL ACTIVITY WARNING: "GlaxoSmithKline plc (LON:GSK) PT Lowered to GBX 1,450" was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of USA and worldwide trademark & copyright legislation.

GlaxoSmithKline plc is a global healthcare company. The Firm operates through three divisions: Pharmaceuticals, Vaccines and Consumer Healthcare.

Other reports by Click Lancashire

Discuss This Article